Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma
Lamarca, Angela Ostios, L McNamara, Mairead G Garzon, C Gleeson, Jack P Edeline, J Herrero, A Hubner, Richard A Moreno, V Valle, John W
Lamarca, Angela
Ostios, L
McNamara, Mairead G
Garzon, C
Gleeson, Jack P
Edeline, J
Herrero, A
Hubner, Richard A
Moreno, V
Valle, John W
Citations
Altmetric:
Abstract
Precision medicine is a major achievement that has impacted on management of patients diagnosed with advanced cholangiocarcinoma (CCA) over the last decade. Molecular profiling of CCA has identified targetable alterations, such as fibroblast growth factor receptor-2 (FGFR-2) fusions, and has thus led to the development of a wide spectrum of compounds. Despite favourable response rates, especially with the latest generation FGFRi, there are still a proportion of patients who will not achieve a radiological response to treatment, or who will have disease progression as the best response. In addition, for patients who do respond to treatment, secondary resistance frequently develops and mechanisms of such resistance are not fully understood. This review will summarise the current state of development of FGFR inhibitors in CCA, their mechanism of action, activity, and the hypothesised mechanisms of resistance.
Description
Date
2023
Publisher
Collections
Keywords
Type
Article
Citation
Lamarca A, Ostios L, McNamara MG, Garzon C, Gleeson JP, Edeline J, et al. Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma. Cancer Treat Rev. 2023 Sep 16;121:102627. PubMed PMID: 37925878. Epub 2023/11/06. eng.